➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Dow
Johnson and Johnson
AstraZeneca
Moodys

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,808,445

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,808,445
Title:Factor IXa inhibitors
Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes. ##STR00001##
Inventor(s): Sakurada; Isao (Gotemba, JP), Hirabayashi; Tomokazu (Gotemba, JP), Maeda; Yoshitaka (Gotemba, JP), Nagasue; Hiroshi (Gotemba, JP), Mizuno; Takashi (Gotemba, JP), Xu; Jiayi (Marlboro, NJ), Zhang; Ting (Princeton Junction, NJ), Smith; Cameron (Montgomery Village, MD), Parker; Dann (Cranford, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ) Mochida Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:15/303,322
Patent Claims:1. A compound of the Formula (I): ##STR00148## or a pharmaceutically acceptable salt thereof; wherein: n is an integer of 0 or 1; p is an integer of 0 to 5; q is an integer of 0 to 4; r is an integer of 0 to 4; X is a nitrogen atom or CH; Y is an oxygen atom, a sulfur atom or NH (when n=0), Y is a nitrogen atom or CH (when n=1); Z.sup.1, Z.sup.2, Z.sup.3, and Z.sup.4 are each independently a nitrogen atom or CH; each R.sup.1 is a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxyl C.sub.1-6 alkyl group, a C.sub.3-12 cycloalkyl group, a C.sub.1-6 alkoxy group, a halogenated C.sub.1-6 alkoxy group, a C.sub.2-7 alkanoyl group, or a group of --NR.sup.AR.sup.B; R.sup.A and R.sup.B are each independently a hydrogen atom, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group or a C.sub.2-7 alkanoyl group; each R.sup.2 is independently a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a C.sub.3-12 cycloalkyl group, a C.sub.1-6 alkoxy group, or a halogenated C.sub.1-6 alkoxy group; each R.sup.3 is independently a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a C.sub.3-12 cycloalkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group, a cyanated C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy group, a C.sub.1-6 alkoxy C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkoxy group, a C.sub.2-7 alkanoyl group, a C.sub.1-6 alkylthio group, a C.sub.1-6 alkylsulfonyl group, or a group of --NR.sup.AR.sup.B, or oxo; a dotted line in a bicyclic substructure of Formula (I) represented by Formula (II): ##STR00149## represents a single bond when n is 0, or a double bond when n is 1; a substructure of ring A represented by Formula (III): ##STR00150## is a non aromatic heterocyclic group selected from: ##STR00151## is heteroaryl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein p is an integer of 0 to 1.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein q is an integer of 0 to 2.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein r is an integer of 0 to 2.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (V): ##STR00152## in Formula (I) is: ##STR00153##

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein ##STR00154## is: ##STR00155## ##STR00156## wherein R.sup.4 is a hydrogen atom, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxyl C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy C.sub.1-6 alkyl group or a cyanated C.sub.1-6 alkyl group.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (II): ##STR00157## in Formula (I) is: ##STR00158##

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (II): ##STR00159## in Formula (I) is: ##STR00160##

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (III): ##STR00161## in Formula (I) is ##STR00162##

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is a halogen atom, a cyano group, or a C.sub.1-6 alkyl group.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 is a halogen atom.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R.sup.3 is a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy group or oxo.

13. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein: R.sup.4 is a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group or a hydroxyl C.sub.1-6 alkyl group.

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is N-((1S*,4S*,7R*)-2-(3-Aminobenzo[d]isoxazol-7-yl)-2-azabicyclo[2.2.1]hept- an-7-yl)-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Aminoisoxazolo[5,4-c]pyridin-7-yl)-2-azabicyclo[2.2- .1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylbenzo[d]isoxazol-7-yl)-2-azabicyclo[2- .2.1]heptan-7-yl)-2,6-dichloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide- ; N-((1S*,4S*,7R*)-2-(3-Amino-5-chlorobenzo[d]isoxazol-7-yl)-2-azabicyclo[- 2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chlorobenzo[d]isoxazol-7-yl)-2-azabicyclo[2- .2.1]heptan-7-yl)-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzam- ide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-a- zabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)be- nzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)- -2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1H-1,2,4-triazol-1-yl)benzami- de; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-az- abicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1H-1,2,4-triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(pyrimidin-5-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(2-methoxypyrimidin-5-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzam- ide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-a- zabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)be- nzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)- -2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(pyridazin-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(4-(2-hydroxyethyl)-1H-imidazol-1-yl)b- enzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl- )-2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(4-(2-hydroxyethyl)-1H-1,2,3-- triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-(difluoromethyl)-4H-1,2,4-triazol-4- -yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(2-cyanopyrimidin-5-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-y- l)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-(difluoromethyl)-6-oxo-1,6-dihydrop- yridin-3-yl)benzamide; 4-([1,2,4]Triazolo[4,3-a]pyridin-6-yl)-N-((1S*,4S*,7R*)-2-(3-amino-4-chlo- roisoxazolo[5,4-c]pyridin-7-yl)-2-azabicyclo[2.2.1]heptan-7-yl)-2-chlorobe- nzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)- -2-azabicyclo[2.2.1]heptan-7-yl)-4-(1H-benzo[d]imidazol-1-yl)-2-chlorobenz- amide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2- -azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1H-imidazo[4,5-b]pyridin-1-yl)b- enzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl- )-2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-(2-hydroxyethyl)-6-oxo-1,6- -dihydropyridin-3-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-6-oxo-1,6-dihydropyridazin-3- -yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-cyanoisoxazolo[5,4-c]pyridin-7-yl)-2-azabic- yclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl- )benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-(trifluoromethyl)-4H-1,2,4-triazol-- 4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-2-oxo-1,2-dihydropyrimidin-5- -yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-5-oxo-1,5-dihydro-4H-1,2,4-t- riazol-4-yl)benzamide or N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-3-chloro-5-(3-methyl-1H-1,2,4-triazol-1-yl)picoli- namide.

15. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

16. A method of treating a thromboembolic disorder selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, thromboembolic disorders in the chambers of the heart, unstable angina, an acute coronary syndrome, atrial fibrillation, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, further comprising administering to said patient at least one anticoagulant agent which is a thrombin inhibitor, a thrombin receptor (PAR-1) antagonist, a factor VIIa inhibitor, factor VIIIa inhibitor, a factor IXa inhibitor, a factor Xa inhibitor, a factor XIa inhibitor, TAFI and fibrinogen inhibitors.

18. A pharmaceutical composition comprising: a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent which is (a) an anticoagulant, (b) an anti-thrombin agent, (c) an anti-platelet agent, (d) a fibrinolytic, (e) a hypolipidemic agent, (f) an antihypertensive agent, or (g) an anti-ischemic agent.

19. A pharmaceutical composition comprising: a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent which is (a-1) warfarin, (a-2) heparin, (a-3) aprotinin, (a-4) synthetic pentasaccharide, (a-5) direct acting thrombin inhibitors including hirudin and argatroban, (a-6) a factor VIIa inhibitor, (a-7) a factor VIIIa inhibitor, (a-8) a factor IXa inhibitor different from the compounds of Formula (I), (a-9) a factor Xa inhibitor, (a-10) a factor XIa inhibitor, (a-11) a thrombin inhibitor, (a-12) a TAFI, (a-13) a fibrinogen inhibitor, (b-1) a boroarginine derivative, (b-2) a boropeptide, (b-3) heparin, (b-4) hirudin, (b-5) argatroban, (c-1) a NSAID, (c-2) a IIb/IIIa antagonist, (c-3) a thromboxane-A2-receptor antagonist, (c-4) a thromboxane-A2-synthetase inhibitor, (c-5) a PDE-III inhibitor, (c-6) a PDE V inhibitor, (c-7) a ADP receptor antagonist, (c-8) an antagonist of the purinergic receptor P2Y1, (c-9) an antagonist of the purinergic receptor P2Y12, (d-1) tissue plasminogen activator (TPA, natural or recombinant) and modified forms thereof, (d-2) anistreplase, (d-3) urokinase, (d-4) streptokinase, (d-5) tenecteplase (TNK), (d-6) lanoteplase (nPA), (d-7) a factor VIIa inhibitor, (d-8) a PAI-I inhibitor, (d-9) an alpha-2-antiplasmin inhibitor, (d-10) an anisoylated plasminogen streptokinase activator complex, (e-1) a HMG-CoA reductase inhibitor, (e-2) a squalene synthetase inhibitor, (e-3) a fibrate, (e-4) a bile acid sequestrant, (e-5) an ACAT inhibitor, (e-6) a MTP inhibitor, (e-7) a lipooxygenase inhibitor, (e-8) a cholesterol absorption inhibitor, (e-9) a cholesterol ester transfer protein inhibitor, (f-1) an alpha adrenergic blocker, (f-2) a beta adrenergic blocker, (f-3) a calcium channel blocker, (f-4) a diuretics, (f-5) a renin inhibitor, (f-6) an angiotensin-converting enzyme inhibitor, (f-7) an angiotensin-II-receptor antagonist, (f-8) an ET receptor antagonist, (f-9) a Dual ET/All antagonist, (f-10) a neutral endopeptidase inhibitors, (f-11) a vasopepsidase inhibitor, (g-1) a Class I agent, (g-2) a Class II agent, (g-3) a Class III agent, a (g-4) Class IV agent, (g-5) a K+ cannel opener, (g-6) an IKur inhibitor or (g-7) a cardiac glycoside.

Summary for Patent:   Start Trial

PCT Information
PCT FiledApril 10, 2015PCT Application Number:PCT/US2015/025219
PCT Publication Date:October 22, 2015PCT Publication Number:WO2015/160634

Details for Patent 9,808,445

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Hlthcare TRASYLOL aprotinin INJECTABLE;INJECTION 020304 001 1994-02-07   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) Mochida Pharmaceutical Co., Ltd. (Tokyo, JP) 2034-04-16 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) Mochida Pharmaceutical Co., Ltd. (Tokyo, JP) 2034-04-16 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) Mochida Pharmaceutical Co., Ltd. (Tokyo, JP) 2034-04-16 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) Mochida Pharmaceutical Co., Ltd. (Tokyo, JP) 2034-04-16 DISCN search
Genentech TNKASE tenecteplase VIAL 103909 001 2000-06-02   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) Mochida Pharmaceutical Co., Ltd. (Tokyo, JP) 2034-04-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Merck
Mallinckrodt
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.